UBS Group AG Reduces Stock Position in Evolus, Inc. $EOLS

UBS Group AG lessened its position in Evolus, Inc. (NASDAQ:EOLS) by 14.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 881,369 shares of the company’s stock after selling 148,747 shares during the period. UBS Group AG’s holdings in Evolus were worth $5,861,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of EOLS. Nantahala Capital Management LLC raised its stake in shares of Evolus by 33.2% during the third quarter. Nantahala Capital Management LLC now owns 5,726,857 shares of the company’s stock valued at $35,163,000 after acquiring an additional 1,428,931 shares during the last quarter. Caligan Partners LP grew its stake in shares of Evolus by 23.8% in the third quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock worth $25,413,000 after purchasing an additional 796,973 shares during the last quarter. Vanguard Group Inc. increased its holdings in Evolus by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,428,943 shares of the company’s stock valued at $21,054,000 after purchasing an additional 110,693 shares during the period. Soleus Capital Management L.P. increased its holdings in Evolus by 96.4% during the 2nd quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock valued at $19,516,000 after purchasing an additional 1,039,842 shares during the period. Finally, Millennium Management LLC raised its position in Evolus by 1.7% during the 1st quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock valued at $16,746,000 after purchasing an additional 23,605 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Insiders Place Their Bets

In other Evolus news, insider Rui Avelar sold 29,996 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total transaction of $146,680.44. Following the completion of the transaction, the insider owned 430,542 shares of the company’s stock, valued at approximately $2,105,350.38. This trade represents a 6.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider David Moatazedi sold 116,720 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total transaction of $570,760.80. Following the sale, the insider owned 618,369 shares in the company, valued at approximately $3,023,824.41. This trade represents a 15.88% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 163,504 shares of company stock valued at $797,184. 5.00% of the stock is owned by corporate insiders.

Evolus Stock Performance

Evolus stock opened at $6.59 on Thursday. Evolus, Inc. has a fifty-two week low of $3.86 and a fifty-two week high of $10.62. The stock’s 50 day simple moving average is $5.10 and its two-hundred day simple moving average is $5.61. The stock has a market cap of $434.02 million, a price-to-earnings ratio of -9.84 and a beta of 1.28.

Evolus (NASDAQ:EOLS) last released its earnings results on Monday, May 4th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The firm had revenue of $73.14 million during the quarter, compared to the consensus estimate of $72.52 million. During the same period in the previous year, the firm posted ($0.30) EPS. On average, analysts predict that Evolus, Inc. will post -0.41 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on EOLS. Mizuho set a $15.00 price objective on Evolus in a report on Wednesday, February 4th. Wall Street Zen downgraded Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. Weiss Ratings raised Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. BTIG Research reiterated a “buy” rating and issued a $13.00 price target on shares of Evolus in a report on Wednesday, March 4th. Finally, HC Wainwright reduced their price objective on shares of Evolus from $20.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Evolus has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.